Trial Profile
A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group, Phase III Clinical Trial For The Efficacy, Tolerability And Safety Of Two Doses Of Rasagiline Mesylate In Early Parkinson's Disease (PD) Patients Not Treated With Levodopa.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 02 Nov 2021
Price :
$35
*
At a glance
- Drugs Rasagiline (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; Therapeutic Use
- Acronyms TEMPO
- Sponsors Teva Neuroscience; Teva Pharmaceutical Industries
- 06 Aug 2010 Results published in the International Journal of Neuroscience in June 2010.
- 01 Sep 2006 Status change
- 27 Nov 2005 New trial record.